A transformative clinical protocol has eliminated the requirement for myeloablative conditioning in kidney transplantation, addressing one of the field’s most significant toxicity challenges. The study, published in Science Translational Medicine (June 2026), demonstrates that combining donor bone marrow with recipient regulatory T cells achieves stable hematopoietic chimerism without any irradiation or chemotherapy exposure.
This represents a major paradigm shift compared to conventional approaches: traditional myeloablative conditioning carries high toxicity, while the novel protocol operates with minimal conditioning burden. By establishing immune tolerance through cellular combination rather than ablation, researchers have created a pathway that preserves patient safety while maintaining robust, durable organ acceptance. The minimal toxicity profile could fundamentally alter who qualifies for transplantation and improve long-term health outcomes.
Read the full article on GMJ Newsroom.
Was this article helpful?
